Literature DB >> 22426207

TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice.

Line S Reinert1, Louis Harder, Christian K Holm, Marie B Iversen, Kristy A Horan, Frederik Dagnæs-Hansen, Benedicte P Ulhøi, Thomas H Holm, Trine H Mogensen, Trevor Owens, Jens R Nyengaard, Allan R Thomsen, Søren R Paludan.   

Abstract

Herpes simplex viruses (HSVs) are highly prevalent neurotropic viruses. While they can replicate lytically in cells of the epithelial lineage, causing lesions on mucocutaneous surfaces, HSVs also establish latent infections in neurons, which act as reservoirs of virus for subsequent reactivation events. Immunological control of HSV involves activation of innate immune pattern-recognition receptors such as TLR3, which detects double-stranded RNA and induces type I IFN expression. Humans with defects in the TLR3/IFN pathway have an elevated susceptibility to HSV infections of the CNS. However, it is not known what cell type mediates the role of TLR3 in the immunological control of HSV, and it is not known whether TLR3 sensing occurs prior to or after CNS entry. Here, we show that in mice TLR3 provides early control of HSV-2 infection immediately after entry into the CNS by mediating type I IFN responses in astrocytes. Tlr3-/- mice were hypersusceptible to HSV-2 infection in the CNS after vaginal inoculation. HSV-2 exhibited broader neurotropism in Tlr3-/- mice than it did in WT mice, with astrocytes being most abundantly infected. Tlr3-/- mice did not exhibit a global defect in innate immune responses to HSV, but astrocytes were defective in HSV-induced type I IFN production. Thus, TLR3 acts in astrocytes to sense HSV-2 infection immediately after entry into the CNS, possibly preventing HSV from spreading beyond the neurons mediating entry into the CNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426207      PMCID: PMC3314467          DOI: 10.1172/JCI60893

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.

Authors:  Stéphanie Dupuis; Emmanuelle Jouanguy; Sami Al-Hajjar; Claire Fieschi; Ibrahim Zaid Al-Mohsen; Suliman Al-Jumaah; Kun Yang; Ariane Chapgier; Céline Eidenschenk; Pierre Eid; Abdulaziz Al Ghonaium; Haysam Tufenkeji; Husn Frayha; Suleiman Al-Gazlan; Hassan Al-Rayes; Robert D Schreiber; Ion Gresser; Jean-Laurent Casanova
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

Review 2.  Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's.

Authors:  Kenneth L Tyler
Journal:  Herpes       Date:  2004-06

3.  Does Toll-like receptor 3 play a biological role in virus infections?

Authors:  Kurt H Edelmann; Sarah Richardson-Burns; Lena Alexopoulou; Kenneth L Tyler; Richard A Flavell; Michael B A Oldstone
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

4.  Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9.

Authors:  Anne Krug; Gary D Luker; Winfried Barchet; David A Leib; Shizuo Akira; Marco Colonna
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

5.  Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis.

Authors:  Evelyn A Kurt-Jones; Melvin Chan; Shenghua Zhou; Jennifer Wang; George Reed; Roderick Bronson; Michelle M Arnold; David M Knipe; Robert W Finberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-22       Impact factor: 11.205

6.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection.

Authors:  Koichi Tabeta; Philippe Georgel; Edith Janssen; Xin Du; Kasper Hoebe; Karine Crozat; Suzanne Mudd; Louis Shamel; Sosathya Sovath; Jason Goode; Lena Alexopoulou; Richard A Flavell; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

7.  Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections.

Authors:  O Adams; K Besken; C Oberdörfer; C R MacKenzie; O Takikawa; W Däubener
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; X Chen; D J Fink; R L Hendricks
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

9.  Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity.

Authors:  Yiqi Guo; Magali Audry; Michael Ciancanelli; Laia Alsina; Joana Azevedo; Melina Herman; Esperanza Anguiano; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Elodie Pauwels; Paul Bastard Philippe; Rebeca Pérez de Diego; Annabelle Cardon; Guillaume Vogt; Capucine Picard; Zafitsara Zo Andrianirina; Flore Rozenberg; Pierre Lebon; Sabine Plancoulaine; Marc Tardieu; Emmanuelle Jouanguy; Damien Chaussabel; Frederic Geissmann; Laurent Abel; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  J Exp Med       Date:  2011-09-12       Impact factor: 14.307

10.  Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells.

Authors:  Jennifer Lund; Ayuko Sato; Shizuo Akira; Ruslan Medzhitov; Akiko Iwasaki
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  78 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

2.  An innate antiviral pathway acting before interferons at epithelial surfaces.

Authors:  Marie B Iversen; Line S Reinert; Martin K Thomsen; Ieva Bagdonaite; Ramya Nandakumar; Natalia Cheshenko; Thaneas Prabakaran; Sergey Y Vakhrushev; Malgosha Krzyzowska; Sine K Kratholm; Fernando Ruiz-Perez; Steen V Petersen; Stanislas Goriely; Bo Martin Bibby; Kristina Eriksson; Jürgen Ruland; Allan R Thomsen; Betsy C Herold; Hans H Wandall; Sebastian Frische; Christian K Holm; Søren R Paludan
Journal:  Nat Immunol       Date:  2015-11-30       Impact factor: 25.606

3.  Herpes Simplex Virus and Interferon Signaling Induce Novel Autophagic Clusters in Sensory Neurons.

Authors:  Sarah Katzenell; David A Leib
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 4.  Activation and regulation of DNA-driven immune responses.

Authors:  Søren R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2015-06       Impact factor: 11.056

Review 5.  New advances on glial activation in health and disease.

Authors:  Kim Mai Lee; Andrew G MacLean
Journal:  World J Virol       Date:  2015-05-12

Review 6.  Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease.

Authors:  Evelyn A Kurt-Jones; Megan H Orzalli; David M Knipe
Journal:  Adv Anat Embryol Cell Biol       Date:  2017       Impact factor: 1.231

7.  CRF-amplified neuronal TLR4/MCP-1 signaling regulates alcohol self-administration.

Authors:  Harry L June; Juan Liu; Kaitlin T Warnock; Kimberly A Bell; Irina Balan; Dominique Bollino; Adam Puche; Laure Aurelian
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

Review 8.  A virological view of innate immune recognition.

Authors:  Akiko Iwasaki
Journal:  Annu Rev Microbiol       Date:  2012       Impact factor: 15.500

9.  PNKP knockdown by RNA interference inhibits herpes simplex virus-1 replication in astrocytes.

Authors:  Lei Yue; Sujie Guo; Xia Cao; Ying Zhang; Le Sun; Longding Liu; Min Yan; Qihan Li
Journal:  Virol Sin       Date:  2013-11-06       Impact factor: 4.327

10.  αvβ3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1.

Authors:  Tatiana Gianni; Valerio Leoni; Liudmila S Chesnokova; Lindsey M Hutt-Fletcher; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.